Package 0002-1506-61

{"route": ["SUBCUTANEOUS"], "spl_id": "371ba02d-d590-4295-a315-b5efe4596614", "openfda": {"nui": ["N0000194015", "N0000000152", "N0000178480", "N0000020058"], "upc": ["0300023002013", "0300021152017", "0300022423017", "0300024612112", "0300024052116", "0300024304116", "0300021243012", "0300024523111"], "unii": ["OYN3CCI6QE"], "rxcui": ["2601743", "2601746", "2601755", "2601758", "2601761", "2601764", "2601767", "2601770", "2601773", "2601776", "2601784", "2601785", "2644396", "2644399", "2644401", "2644403", "2644405", "2644407", "2644409", "2644411", "2644413", "2644415", "2644417", "2644419", "2732437", "2732442", "2732446", "2732449", "2732452", "2732456", "2733666", "2733668", "2733670", "2733671", "2733673", "2733675", "2734623", "2734628", "2734632", "2734636", "2734640", "2734644", "2735286", "2735288", "2735290", "2735292", "2735294", "2735297"], "spl_set_id": ["d2d7da5d-ad07-4228-955f-cf7e355c8cc0"], "pharm_class_epc": ["Glucose-dependent Insulinotropic Polypeptide Receptor Agonist [EPC]", "GLP-1 Receptor Agonist [EPC]"], "pharm_class_moa": ["G-Protein-linked Receptor Interactions [MoA]", "Glucagon-like Peptide-1 (GLP-1) Agonists [MoA]"], "manufacturer_name": ["Eli Lilly and Company"], "is_original_packager": [true]}, "finished": true, "packaging": [{"sample": true, "description": "4 SYRINGE in 1 CARTON (0002-1506-61)  / .5 mL in 1 SYRINGE", "package_ndc": "0002-1506-61", "marketing_start_date": "20220608"}, {"sample": false, "description": "4 SYRINGE in 1 CARTON (0002-1506-80)  / .5 mL in 1 SYRINGE (0002-1506-01)", "package_ndc": "0002-1506-80", "marketing_start_date": "20220513"}], "brand_name": "Mounjaro", "product_id": "0002-1506_371ba02d-d590-4295-a315-b5efe4596614", "dosage_form": "INJECTION, SOLUTION", "pharm_class": ["G-Protein-linked Receptor Interactions [MoA]", "GLP-1 Receptor Agonist [EPC]", "Glucagon-like Peptide-1 (GLP-1) Agonists [MoA]", "Glucose-dependent Insulinotropic Polypeptide Receptor Agonist [EPC]"], "product_ndc": "0002-1506", "generic_name": "tirzepatide", "labeler_name": "Eli Lilly and Company", "product_type": "HUMAN PRESCRIPTION DRUG", "brand_name_base": "Mounjaro", "active_ingredients": [{"name": "TIRZEPATIDE", "strength": "2.5 mg/.5mL"}], "application_number": "NDA215866", "marketing_category": "NDA", "marketing_start_date": "20220513", "listing_expiration_date": "20271231"}